The average price of medicines is reduced by 56%
Yangcheng Evening News reporter Chen Zeyun
On June 28, Shanghai Sunshine Pharmaceutical Purchasing Network issued the "Notice on Announcement of the Results of the National Drug Centralized Procurement", which means that the results of the fifth batch of national drug centralized procurement were officially announced.
A total of 61 drugs were successfully bid, and one drug failed the bid, involving 251 products from 148 companies, and the selected drugs dropped by an average of 56%.
According to previously announced documents, the total amount of drugs involved in the fifth batch of national drug procurement on the provincial procurement platform in 2020 will be as high as 55 billion yuan. From the quantity to the procurement amount, it is the largest scale since the previous centralized procurement.
According to the National Medical Insurance Administration, patients across the country are expected to use the drugs after the price cuts in October 2021.
What are the new changes in this collection compared to the previous ones?
What are the major varieties of 61 drugs?
What new changes will it bring to the common people and corporate market competition?
A reporter from the Yangcheng Evening News sorted out the "most" of this collection for you.
The biggest drop has drug prices plummeting 98%
The price of esomeprazole injection for the treatment of acute gastric ulcers has been reduced from 65 yuan per tube to about 4 yuan per tube, which can save 610 yuan per treatment cycle; the new-generation diabetes drug saxagliptin is reduced by 62%, and the monthly cost is reduced by 225 yuan dropped to below 90 yuan... Another batch of centrally sourced drugs will usher in a big price cut.
It is reported that this collection of products covers common diseases such as high blood pressure, anti-allergic, anti-infection, chronic disease drugs, and drugs for major diseases such as lung cancer. The average price is reduced by 56%.
Among the 61 winning bidders, Qilu Pharmaceutical's rivaroxaban (10mg) achieved a 98% drop, the highest drop in this round of drugs.
Behind the diving price cut is fierce competition. In terms of varieties, the number of companies that have declared rivaroxaban oral regular release doses is the most, reaching 24.
According to the results of the proposed selection, 10, 8 and 7 companies of the 3 product specifications of rivaroxaban (10mg, 15mg, 20mg) were selected respectively. Among them, Qilu Pharmaceutical won the bid with 0.529 yuan/tablet, the highest drop.
Huahai Pharmaceutical was selected at 4.15 yuan/piece and 5.18 yuan/piece respectively, with a price drop of approximately 85%.
The original research manufacturer Bayer was not selected.
In this centralized procurement, there were also "a few cents" of medicines reappearing.
For example, Yuanda Pharmaceutical’s metoprolol tablets were quoted at an ultra-low price of 8 cents a piece, and they won the bids at the same time as Yiling Pharmaceuticals, Buchang Pharmaceuticals and other pharmaceutical companies.
The most "new" battlefield injections fight fiercely
This round of centralized procurement is the first centralized procurement with injections as the main force.
In this round of centralized collection, there were 29 injections, accounting for half.
There are more than 13 competitors for esomeprazole injection, ceftazidime injection, and ceftriaxone injection.
Why is the competition for injections so fierce?
Insiders pointed out that, unlike oral dosage forms, injections are mainly used in medical institutions.
The products selected in centralized procurement will occupy most of the market in public hospitals and are unlikely to be deployed in the out-of-hospital market. This is also destined to become the most tragic field in centralized procurement.
In the fifth batch of centralized drug procurement organized by countries, 11 products of 10 foreign pharmaceutical companies are planned to be selected, involving French Sanofi, American General Motors, German Fresenius, Israel Teva, etc. The number of foreign companies selected is higher The four batches have improved significantly. It can be said that the centralized procurement market for injections is an unavoidable battlefield for multinational pharmaceutical companies.
In order to keep the original share, a number of original research pharmaceutical companies took the initiative to cut prices.
Among them, German Braun Medical cut the price of omega-3 fish oil medium/long-chain fat emulsion injection by 83%, which is lower than the prices of local pharmaceutical companies Kelun and Shenzhen Haibin Pharmaceutical.
Sanofi’s oxaliplatin injection won the bid at 310.51 yuan per piece, a direct price cut of 80%.
The local pharmaceutical companies are also fiercely competing for the injection market.
Among them, docetaxel is one of the commonly used drugs for cancer treatment, and it has a good effect on breast cancer, ovarian cancer, non-small cell lung cancer, etc. The terminal sales of this drug in 2019 are close to 4 billion yuan.
Six pharmaceutical companies, including Hengrui Pharmaceutical, Qilu Pharmaceutical, Chia Tai Tianqing, and Yangtze River Pharmaceutical, were successfully selected for docetaxel injections, with a decrease of more than 90%. The original manufacturer was unsuccessful.
The most "harvest" pharmaceutical enterprises leading companies become large gatherings
The trend of gathering bid-winning enterprises to "leading enterprises" is becoming more and more obvious.
On the whole, domestic leading companies such as Qilu, Yangtze River, Sino Biotech, Hengrui, and Chia Tai Tianqing are still the main players.
Qilu Pharmaceutical has won major bids in the first four batches of centralized procurement. This time, there were 13 products shortlisted for centralized procurement, 11 of which were selected.
"Infusion giant" Kelun Pharmaceutical was selected for all 11 varieties.
China Biopharmaceutical and Yangzijiang Pharmaceutical both selected 10 varieties.
Large-scale pharmaceutical companies are also more decisive in bargaining prices. This time Hengrui Medicine has 6 varieties on the market. Among them, in the competition of 3 blockbuster varieties such as oxaliplatin and cisatracurium besilate, all of them are The lowest price won the bid, and the quotation is much lower than other winning bidders.
However, while leading companies have drastically cut prices and won the bids, some pharmaceutical companies are still able to win bids with higher prices under the existing quotation framework.
For example, cefazolin sodium for injection, CSPC won the Shanxi, Liaoning and other markets at 2.94 yuan/bottle, while at the same time, Chengdu Better Pharmaceuticals won the Guangxi and Fujian markets at 10.7 yuan/bottle. The importance of strategy has become increasingly prominent.
The most "thrilling" these companies step on the car
Participating countries' centralized procurement of drugs, whether oral or injectable, has a hard standard that must pass the drug consistency evaluation.
Since May last year, the consistency evaluation of chemical injections has officially kicked off.
On June 22, the State Food and Drug Administration announced that 9 varieties of metoprolol tartrate tablets and ceftriaxone sodium for injection were all newly reviewed companies. Shanghai Shangyao Xinya, Suzhou Aimeijin Pharmaceutical, and Zhuhai Homologous Twenty pharmaceutical companies, including the Pharmaceutical Industry, "stepped on the point" and passed the review and caught up with the "last train" of the national procurement bid.
This has also led to the further intensification of competition for multiple drugs. For example, AstraZeneca’s metoprolol tartrate tablets added 7 "competitors" overnight before the bid opening, which ultimately prompted the product to appear at 8 cents per tablet. The super low price.